Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Benchmarking an Oral Anticoagulant Treatment Rate in Patients With Nonvalvular Atrial Fibrillation
NCT02919982 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to establish a benchmark for rate of prescription of oral anticoagulants (OA) in patients with non-valvular atrial fibrillation (NVAF) seen in an ambulatory care setting, based on independent medical assessment of clinical data and physician and patient surveys. The study will also assess reasons for not prescribing OA to prevent thromboembolic complications in patients with NVAF seen in ambulatory care, and patients' perspectives of non-use of OA for treatment of NVAF.
Conditions Studied
Study Locations (20)
Florida
- Clearwater Cardiovascular & Interventional Consultants MD PA — Clearwater
- Holy Cross Hospital, Inc. — Fort Lauderdale
- Heartwell LLP — Miami
- Cardiac Institute of the Palm Beaches — Palm Beach Gardens
Michigan
- Michigan Heart - St. Joseph Mercy Health System — Ann Arbor
- Munson Medical Group — Traverse City
Texas
- The Heart Institute of East Texas — Lufkin
- Waco Cardiology Associates — Waco
Virginia
- Centra Health, Inc. dba Stroobants Cardiovascular Center — Lynchburg
- Virginia Cardiovascular Specialists — Richmond
Alaska
- Alaska Heart Institute — Anchorage
California
- Orange County Heart Institute and Research Center — Orange
Illinois
- Adventist Health Partners, Inc. Amita Health — Hinsdale
Maryland
- Delmarva Heart LLC — Salisbury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 817 participants |
| Start Date | 2017-01 |
| Est. Completion | 2019-09 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02919982
The ClinicalTrials.gov registry entry for NCT02919982 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 817 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baim Institute for Clinical Research, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Nonvalvular Atrial Fibrillation appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT02919982 reports 20 study locations spanning 14 distinct geographic areas — top geographies include Florida, Michigan, Texas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT02919982 about?
NCT02919982 is a clinical study titled "Benchmarking an Oral Anticoagulant Treatment Rate in Patients With Nonvalvular Atrial Fibrillation". The purpose of this study is to establish a benchmark for rate of prescription of oral anticoagulants (OA) in patients with non-valvular atrial fibrillation (NVAF) seen in an ambulatory care setting, based on independent medical assessment of clinical data and physician and patient surveys. The stud...
What is the current status of trial NCT02919982?
This trial is currently completed. The enrollment target is 817 participants. The study started on 2017-01. Estimated completion is 2019-09.
What conditions does trial NCT02919982 study?
This clinical trial studies the following conditions: Nonvalvular Atrial Fibrillation. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
Who is sponsoring clinical trial NCT02919982?
This trial is sponsored by Baim Institute for Clinical Research, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT02919982 being conducted?
This trial has 20 study locations across Alaska, California, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.